Does Rallies show 13F holders for SGRY?

Yes. Rallies tracks hedge fund and 13F ownership data for SGRY, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SGRY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SGRY. It does not provide personalized investment advice.

SGRY (Surgery Partners, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Surgery Partners, Inc. Common Stock (SGRY) is a publicly traded Healthcare sector company. As of May 20, 2026, SGRY trades at $13.52 with a market cap of $1.82B and a P/E ratio of -23.18. SGRY moved -1.46% today. Year to date, SGRY is -12.06%; over the trailing twelve months it is -41.85%. Its 52-week range spans $11.41 to $33.37. Analyst consensus is buy with an average price target of $19.75. Rallies surfaces SGRY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SGRY stock?

Hedge funds tracked by Rallies that own SGRY include Pentwater Capital, King Street, Davidson Kempner, Glenview Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Surgery Partners, Inc. Common Stock.

SGRY Key Metrics

Key financial metrics for SGRY
Metric	Value
Price	$13.52
Market Cap	$1.82B
P/E Ratio	-23.18
EPS	$-0.59
Dividend Yield	0.00%
52-Week High	$33.37
52-Week Low	$11.41
Volume	764.58K
Avg Volume	0
Revenue (TTM)	$3.34B
Net Income	$97.10M
Gross Margin	0.00%

Top Hedge Funds Holding SGRY

Pentwater Capital holds 12.65M shares of SGRY, changed +26.55% as of Mar 31, 2026.
King Street holds 10.23M shares of SGRY, changed +0.00% as of Mar 31, 2026.
Davidson Kempner holds 3.34M shares of SGRY, changed +40.69% as of Mar 31, 2026.
Glenview Capital holds 1.80M shares of SGRY, changed -53.34% as of Mar 31, 2026.
Farallon Capital holds 1.74M shares of SGRY, changed +0.00% as of Sep 30, 2025.

Latest SGRY News

Surgery Partners Q1 Revenue Climbs 4.5% to $810.9M, EBITDA $102.3M — May 5, 2026
Surgery Partners Forecasts 4% Q4 Growth, Authorizes $200M Buyback and M&A Spend — Mar 3, 2026
Surgery Partners Misses Q4 EPS, Sales Rise 2.4% to $885M — Mar 3, 2026
Surgery Partners Reports Q4 Revenue of $885M, EBITDA Margin Falls to 17.7% — Mar 3, 2026
Surgery Partners EPS Misses by 60%, Sales Guidance Cut to $3.35–$3.45 Billion — Mar 3, 2026

Recent SGRY Insider Trades

Doherty David T sold 8.87K (~$110.84K) on Mar 16, 2026.
Evans Jason Eric sold 20.40K (~$254.39K) on Mar 16, 2026.
Burkhalter Danielle sold 3.47K (~$44.51K) on Mar 13, 2026.

SGRY Analyst Consensus

11 analysts cover SGRY: 0 strong buy, 8 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $19.75.

Common questions about SGRY

Who owns SGRY stock?: Hedge funds tracked by Rallies that own SGRY include Pentwater Capital, King Street, Davidson Kempner, Glenview Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Surgery Partners, Inc. Common Stock.
Does Rallies show 13F holders for SGRY?: Yes. Rallies tracks hedge fund and 13F ownership data for SGRY, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SGRY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SGRY. It does not provide personalized investment advice.